The increasing prevalence of gastrointestinal diseases is driving the demand for stool diagnosis. Gastrointestinal diseases can cause many symptoms, including diarrhea, constipation, abdominal pain, and nausea. Various conditions, including infections and inflammatory bowel disease, can cause these symptoms. Stool tests can detect the presence of infectious agents such as bacteria, viruses, and parasites, as well as biomarkers of inflammation. In addition to the growing demand for stool diagnosis for gastrointestinal diseases, there is increasing interest in using stool tests to monitor the gut microbiome. Stool tests can provide information about the composition and function of the microbiome, which can be useful for identifying dysbiosis (an imbalance in the microbiome) and guiding interventions to improve gut health.
Access full Report @ https://www.databridgemarketresearch.com/pt/reports/asia-pacific-stool-diagnostic-market
Data Bridge Market Research analyses that the Asia-Pacific Stool Diagnostic Market is expected to grow at a CAGR of 7.1% from 2023 to 2030 and reach USD 452,156.67 thousand by 2030. The rise in awareness regarding the importance of stool diagnostics in diagnosing gastrointestinal diseases is expected to propel the market's growth.
Key Findings of the Study
INCREASING PREVALENCE OF OESOPHAGEAL, COLORECTAL, AND GASTRIC CANCERS
The increasing prevalence of oesophageal, colorectal, and gastric cancers drives the demand for stool diagnosis. These types of cancers affect the digestive system and can cause a wide range of changes in bowel habits.
Gastric cancer is also a significant health concern, particularly in Asia, where it is more prevalent. Stool tests can detect biomarkers associated with gastric cancer, such as Helicobacter pylori (H. pylori) infection, a leading cause of the disease.
Stool diagnosis is an important tool for the early detection and monitoring of these types of cancers. Stool tests can detect the presence of cancer-associated biomarkers, such as blood, DNA, and proteins. This can allow for earlier detection and intervention, improving patient outcomes and reducing the burden of these types of cancers. Stool tests can detect the presence of biomarkers that indicate the presence of cancer, such as blood in the stool (which can be a sign of colorectal cancer) or tumor DNA (which can be a sign of oesophageal or gastric cancer).
Oesophageal cancer is particularly prevalent in Asia, where it is a leading cause of cancer-related deaths. Stool tests can detect biomarkers associated with oesophageal cancer, such as DNA mutations and tumor-specific proteins. Using stool tests for oesophageal cancer screening and monitoring is becoming increasingly important in Asia, where the disease burden is high.
Fecal occult blood tests (FOBT) and fecal immunochemical tests (FIT) are commonly used for colorectal cancer screening and can detect blood and other biomarkers associated with the disease. Stool DNA tests, which detect specific DNA mutations associated with colorectal cancer, are also becoming increasingly available.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand, Pricing in USD
|
|
Segments Covered
|
By Test Type (Fecal Occult Blood Test, Fecal Biomarkers Test, Pathogen Tests, Stool Antigen Test, Fecal Elastase Test, Microscopy Test, and Other Tests), Product Type (Instruments and Reagents), Mode (Laboratories Based Testing and Point of Care Testing), Application (Irritable Bowel Syndrome, Ulcerative Colitis, Crohn's Disease, Cancer, Diarrhea, Hemorrhoids, and Others), End User (Hospitals, Diagnostic Centers, Laboratory, Specialty Clinics, Academic Institutions, and Research Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, Online Sales, and Others)
|
|
Countries Covered
|
Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, New Zealand, Vietnam, Taiwan, Brunei, Nepal, Bangladesh, Sri Lanka, Pakistan, Hong Kong, Maldives, Mongolia, Cambodia, Laos, and Rest of Asia-Pacific
|
|
Market Players Covered
|
Abbott (U.S.), Meridian Bioscience Inc. (U.S.), BIOMERIEUX (France), Beckman Coulter, Inc. (Subsidiary of Danaher) (U.S.), DiaSorin S.p.A. (Italy), Runmei (China), Molbio Diagnostics Pvt. Ltd. (India), Quidel Corporation (U.S.), Prenetics Limited (China), Sekisui Diagnostics (A Part of SEKISUI Chemical Co. Ltd.) (U.S.), BioVendor Group (Czech Republic), LifeSign LLC (U.S.), Alfa Scientific Designs (U.S.), Inc., Eiken Chemical Co., Ltd. (Japan), SD Biosensor, INC. (Republic of Korea), Cenogenics Corporation (U.S.), TransGen Biotech Co., Ltd. (China), AdvaCare Pharma (U.S.), Kibion GmbH (Germany), and Beijing Huagen Anbang Technology Co., Ltd. (China) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The stool diagnostic market is segmented into test type, product type, mode, application, end user, and distribution channel.
- On the basis of test type, the Asia-Pacific stool diagnostic market is segmented into fecal occult blood test, fecal biomarkers test, pathogen tests, stool antigen test, fecal elastase test, microscopy test, and other tests.
In 2023, the pathogen test segment is anticipated to dominate the stool diagnostic market.
In 2023, the pathogen test segment is expected to dominate the market due to rising urbanization and western food adoption, leading to gastrointestinal infections across the region. The pathogen test segment is expected to reach the highest CAGR of 7.7% in 2023-2030.
- On the basis of product type, the Asia-Pacific stool diagnostic market is segmented into instruments and reagents. The instruments segment is sub-segmented into microscopes, microscopes slides, microscope cover slip, fecalyzers, digital scales, and others. In 2023, the reagents segment is expected to dominate the market due to emerging demand for stool biomarkers research for diagnosing several gastrointestinal diseases
- On the basis of mode, the Asia-Pacific stool diagnostic market is segmented into laboratories based testing and point of care testing. In 2023, the laboratories based testing segment is expected to dominate the market due to the increase in gastrointestinal-related disorders such as ulcerative colitis causing serious health issues such as chronic disorders
- On the basis of application, the Asia-Pacific stool diagnostic market is segmented into irritable bowel syndrome, ulcerative colitis, crohn's disease, cancer, diarrhea, hemorrhoids, and others. In 2023, the diarrhea segment is expected to dominate the market due to the increased unhealthy food habits
- On the basis of end user, the Asia-Pacific stool diagnostic market is segmented into hospitals, diagnostic centers, laboratory, specialty clinics, academic institutions and research centers, and others. In 2023, the hospitals segment is expected to dominate the market due to the presence of advanced instrumentation, expert surgeons, and facilities for diagnosis through stool testing in hospitals
- On the basis of distribution channel, the Asia-Pacific stool diagnostic market is segmented into direct tenders, retail sales, online sales, and others.
In 2023, the diarrhea segment is projected to hold the largest share of the application segment in the Stool diagnostic market.
In 2023, the diarrhea segment is expected to dominate the market due to the increased unhealthy food habits. The diarrhea segment is expected to grow with a CAGR of 8.2% from 2023 to 2030.
Major Players
Data Bridge Market Research recognizes the following companies as the major Stool diagnostic market players in Stool diagnostic market are Abbott (U.S.), Meridian Bioscience Inc. (U.S.), BIOMERIEUX (France), Beckman Coulter, Inc. (Subsidiary of Danaher) (U.S.), DiaSorin S.p.A. (Italy), Runmei (China), Molbio Diagnostics Pvt. Ltd. (India), Quidel Corporation (U.S.), Prenetics Limited (Republic), LifeSign LLC (U.S.), Alfa Scientific Designs (U.S.), Inc., Eiken Chemical Co., Ltd. (Japan), SD Biosensor, INC. (Republic of Korea), Cenogenics Corporation (U.S.), TransGen Biotech Co., Ltd. (China), AdvaCare Pharma (U.S.), Kibion GmbH (Germany), and Beijing Huagen Anbang Technology Co., Ltd. (China) among others.
Market Developments
- In November 2022, Eiken Chemical Co., Ltd. announced the launch of a Fully Automated Faecal Immunochemical Test/Faecal Calprotectin Analyzer, "OC-SENSOR Ceres". This product launch helped the company in its product portfolio expansion
- In October 2022, DiaSorin S.p.A. announced that DiaSorin Molecular LLC collaborated with the Biomedical Advanced Research and Development Authority (BARDA) to support the clearance of a CLIA-Walved Molecular Solution for infectious disease testing. The LIAISON NES is designed to allow untrained operators to perform testing for viral and bacterial pathogens using state-of-the-art molecular technology with the intent to support the decentralization of diagnostic testing beyond the hospital setting
- In June 2022, Meridian Bioscience, Inc. announced the launch of two new sample-specific master mixes, Lyo-Read Direct DNA qPCR Stool Mix and Lyo-Read Direct RNA/DNA qPCR Stool Mix. These innovative master mixes improve DNA and RNA molecular detection from crude fecal specimens while allowing room temperature stabilization of diagnostic assays. This product launch would help the company in its product portfolio expansion
- In June 2022, Prenetics Limited (Nasdaq: PRE) announced the introduction of a novel, non-invasive stool DNA at-home screening test named ColoClear by Circle (ColoClear) for detecting early detection signs of colorectal cancer. This product launch helped the company in its product portfolio expansion
- In November 2019, TransGen Biotech Co., Ltd. announced the launch of the MagicPure Stool and Soil Genomic DNA Kit. This kit provides a simple and fast procedure to extract high-quality DNA from stool or soil. This product launch helped the company in its product and line expansion
Regional Analysis
Geographically, the countries covered in the stool diagnostic market report are Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, New Zealand, Vietnam, Taiwan, Brunei, Nepal, Bangladesh, Sri Lanka, Pakistan, Hong Kong, Maldives, Mongolia, Cambodia, Laos, and the rest of Asia-Pacific.
As per Data Bridge Market Research analysis
China is the dominant region in the stool diagnostic market during the forecast period 2023 - 2030
In 2023, China is expected to dominate the Asia-Pacific stool diagnostic market with an 8.69% market share. This is due to higher cases of gastrointestinal diseases and the launch of new test kits by several key market players for stool diagnosis.
For more detailed information about the stool diagnostic market, click here – https://www.databridgemarketresearch.com/pt/reports/asia-pacific-stool-diagnostic-market
